Assessment of the effects of severe obesity and lifestyle risk factors on stage of endometrial cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 1, 2013, Pages 76-81

  Bittoni, Marisa A ^a,b   Fisher, James L ^b   Fowler, Jeffrey M ^c   Maxwell, George L ^d   Paskett, Electra D ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ANTHROPOMETRY; ARTICLE; BODY MASS; CALORIC INTAKE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER STAGING; CLINICAL ASSESSMENT; DEMOGRAPHY; DIET; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FAT INTAKE; FEMALE; FRUIT; GLYCEMIC LOAD; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RACE; RISK FACTOR; TREATMENT OUTCOME; VEGETABLE;

EID: 84872144263     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0843     Document Type: Article

References (24)

1. American Cancer Society. American Cancer Society Facts and Figures 2012. Atlanta: American Cancer Society; 2012.
2. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-43.
3. Temkin S, Pezullo JC, Hellmann M, Lee Y, Abulafia O. Is body mass index an independent risk factor of survival among patients with endometrial cancer? Am J Clin Oncol 2007;30:8-14.
4. Modesitt SC, van Nagell JR. The impact of obesity on the incidence and treatment of gynecologic cancer. Obstet Gynecol Survey 2005;60:683-92.
5. Key TJ, Pike M. The dose-effect of relationship between "unopposed" oestrogens, endometrial mitotic rate: its central role in explaining, predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
6. Everett E, Tamimi H, Greer B. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2003;90:150-7.
7. Pavelka JC, Ben-Schacher I, Fowler JM. Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patients. Gynecol Oncol 2004;95:588-92.
8. Anderson B, Connor JP, Andrews JI, Davis CS, Buller RE, Sorosky JI, et al. Obesity and prognosis in endometrial cancer. Am J Obstet Gynecol 1996;174:1171-9.
9. Cohn DE, Woeste EM, Cacchio S, Zanagnolo VL, Havrilesky LJ, Mariani A. Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstet Gynecol 2007;109:1062-7.
10. von Gruenigen VE, Tian C, Frasure H, Waggoner S, Heys H, Barakat RR. Treatment effects, disease recurrence, and survival in obese women with early endometrial cancer carcinoma. Cancer 2006;107:2786-91.
11. Dalvi TB, Canchola AJ, Horn-Ross PL. Dietary patterns, Mediterranean diet, and endometrial cancer risk. Cancer Causes Control 2007;18:957-66.
12. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis. Brit J Cancer 2008;99:434-41.
13. Patel AV, Feigelson HS, Talbot JT, McCullough ML, Rodriguez C, Patel RC, et al. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer 2008;123:1877-82.
14. John EM, Koo J, Horn-Ross PL. Lifetime physical activity and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2010;19:1276-83.
15. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009;114:121-7.
16. Patterson RE, Kristal AR, Carter R, Fels-Tinker L, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol 1999;9:178-87.
17. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials 1998;19:61-109.
18. FIGO staging for corpus cancer. Br J Obstet Gynaecol 1992;99:440.
19. WHO Expert Committee. Physical Status: The Use and Interpretation of Anthropometry. Geneva: WHO; 1995.
20. StataCorp 2010. Statistical Software: Release 10.0. College Station, TX: Stata Corporation.
21. Reeves KW, Cuyun-Carter G, Rodabough RJ, Lane D, McNeeley SG, Stefanick ML, et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative. Gynecol Oncol 2011;121:376-82.
22. Munstedt K, Wagner M, Kullmer U, Hackethal A, Franke FF. Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes Control 2008;19:909-16.
23. Fenton JI, Hord NG. Stage matters: choosing relevant model systems to address hypotheses in diet and cancer chemoprevention research. Carcinogenesis 2006;7:893-902.
24. Park HA, Lee JS, Kuller LH. Underreporting of dietary intake by body mass index in premenopausal women participating in the Healthy Women Study. Nutr Res Pract 2007;1:231-6.